Bank Julius Baer & Co
NBIX icon

Bank Julius Baer & Co’s Neurocrine Biosciences NBIX Stock Holding History

Bank Julius Baer & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.01M Buy
23,780
+14,162
+147% +$2.1M 0.01% 274
2026
Q1 		$1.24M Sell
9,618
-2,295
-19% -$305K ﹤0.01% 364
2025
Q4 		$1.68M Buy
+11,913
New +$1.73M ﹤0.01% 336
2024
Q1 		– Sell
-1,084
Closed -$143K – 555
2023
Q4 		$143K Sell
1,084
-13
-1% -$1.5K ﹤0.01% 421
2023
Q3 		$123K Buy
+1,097
New +$116K ﹤0.01% 408
2023
Q1 		– Sell
-2,474
Closed -$295K – 604
2022
Q4 		$295K Buy
2,474
+794
+47% +$93K ﹤0.01% 388
2022
Q3 		$178K Buy
+1,680
New +$170K ﹤0.01% 412
2022
Q2 		– Sell
-150
Closed -$14K – 621
2022
Q1 		$14K Buy
+150
New +$12.7K ﹤0.01% 565

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Bank Julius Baer & Co's NBIX Position: Q2 2026 in Review

Bank Julius Baer & Co increased its Neurocrine Biosciences (NBIX) stake by 147% in Q2 2026, buying an estimated $2.1M and bringing the position to 23,780 shares worth $4.01M. The position accounts for 0.01% of the portfolio, ranked #274.

Bank Julius Baer & Co first reported a position in NBIX in Q1 2022 and has held it in 8 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Bank Julius Baer & Co held 23,780 shares of Neurocrine Biosciences worth $4.01M as of Q2 2026.
  • Bank Julius Baer & Co bought 14,162 Neurocrine Biosciences shares in Q2 2026, an estimated $2.1M.
  • Neurocrine Biosciences made up 0.01% of Bank Julius Baer & Co's portfolio in Q2 2026, its #274 holding.
  • Bank Julius Baer & Co first reported a position in Neurocrine Biosciences in Q1 2022 and has held it in 8 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Bank Julius Baer & Co's 13F filing for Q2 2026, filed 10 Aug 2026.